Terrie Curran

Track

Insider profile

Currently holds positions in Myovant Sciences Ltd and Celgene Corp

Performance

Overall performance
3.2
Performance over holding periods
4.2
30 days 90 days 120 days
Average return 4% 8.2% 15.1%
Success rate 33% 68% 82%
Transactions
6 33% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return 15%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance

Positions

Position Company Period
Independent Director Myovant Sciences Ltd Nov. 15, 2016 -
President, Global Inflammation & Immunology Franchise Celgene Corp April 1, 2017 -
Terrie Curran's trades of Phathom Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-01-23 2025-01-21
PlS Planned sale
91,787 +45.9%
13.20
US$2,605,957 		91,787 +45.9% 13.20 US$2,605,957
2024-11-13 2024-11-11
S Sale
48,235 +27.5%
466.85
US$275,479 		48,235 +27.5% 466.85 US$275,479
2024-11-12 2024-11-11
PrS Proposed sale
13,689
168.64
US$2,406,285 		13,689 168.64 US$2,406,285
2024-07-17 2024-07-15
PlS Planned sale
33,848 -8.2%
11.72
US$396,699 		33,848 -8.2% 11.72 US$396,699
2024-03-26 2024-03-22
PlS Planned sale
16,851 -3.9%
9.11
US$153,513 		16,851 -3.9% 9.11 US$153,513
2023-04-07 2023-04-06
B Purchase
12,919 +7.4%
7.82
US$101,025 		12,919 +7.4% 7.82 US$101,025
2023-03-03 2023-03-01
PlS Planned sale
1,436 -0.8%
8.54
US$12,265 		1,436 -0.8% 8.54 US$12,265
2023-01-20 2023-01-20
S Sale
5,821 -3.2%
8.20
US$47,729 		5,821 -3.2% 8.20 US$47,729
2022-11-23 2022-11-21
S Sale
1,526 -1.8%
9.60
US$14,650 		1,526 -1.8% 9.60 US$14,650
2022-05-16 2022-05-13
B Purchase
20,500 +46.5%
7.41
US$151,835 		20,500 +46.5% 7.41 US$151,835
2021-09-13 2021-09-09
PlS Planned sale
4,850 -100.0%
25.58
US$124,063 		4,850 -100.0% 25.58 US$124,063
2021-03-23 2021-03-22
S Sale
1,140 -100.0%
44.08
US$50,256 		1,140 -100.0% 44.08 US$50,256
2021-03-23 2021-03-22
PlS Planned sale
10,373 -90.1%
43.24
US$448,495 		10,373 -90.1% 43.24 US$448,495
2019-09-19 2019-09-18
US Celgene Corp (CELG)
S Sale
6,838 -76.0%
98.31
US$672,244 		6,838 -76.0% 98.31 US$672,244
2019-09-19 2019-09-18
US Celgene Corp (CELG)
S Sale
4,500 -33.4%
98.20
US$441,900 		4,500 -33.4% 98.20 US$441,900
2018-08-30 2018-08-30
B Purchase
170,501
0.10
£17,050 		170,501 0.10 £17,050